MAZE·Nasdaq·US
Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for kidney, metabolic, and related genetic diseases. It uses a human genetics-driven discovery platform and advances small-molecule programs through clinical development and partnerships.
Recent Activity
Updated Oct 10, 2026
–Maze Therapeutics will present previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease in an oral presentation at ASN Kidney Week 2026.
–Maze Therapeutics will also present data from its MZE782 program through two poster presentations at the conference.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.